1


NEWS RELEASE                                            [CELSION(TM) LOGO]




For Further Information Contact:
John Mon                                                Geoffrey Eiten
Celsion Corporation                                     OTC Financial Network
410.290.5390                                            1 888.399.7541 (ext. 13)
john@celsion.com                                        www.otcfn.com


CELSION REPORTS PROGRESS TOWARDS COMPLETION OF BPH CLINICAL TRIALS


COLUMBIA, MD - AUGUST 15, 2001: In a letter to shareholders issued today,
CELSION CORPORATION (AMEX:CLN) reported that it is moving forward towards
completion of its Benign Prostatic Hyperplasia (BPH) Pivotal Phase II Clinical
Trials. The Company reported that it has engaged 10 active clinical sites,
collectively employing over 150 urologists treating more than 20,000 patients
each month. The Company also reported a significant increase in patient
enrollment during recent months. According to the letter, if the acceleration in
enrollment is sustained, enrollment in the trials could be completed by the end
of October 2001.

In the same letter, Celsion updated its shareholders on the progress of its
other businesses including the Pivotal Phase II Clinical Trials of the Company's
investigational system using focused heat to treat breast cancer; the status of
development of its doxorubicin-laden heat activated liposome cancer drug,
currently in large animal toxicity studies; progress in the development of its
heat activated gene therapy; developments arising from its relationship with
Inabata: and its cash position.

Celsion also advised shareholders that, in future, it expects to host quarterly
shareholder conference calls, the first of which will take place on August 28,
2001 at 10:00 a.m. Eastern Daylight Savings Time. Call-in information is
contained in the letter to shareholders, which is available on the Company's web
site at www.celsion.com

ABOUT CELSION: Celsion Corporation, based in Columbia, Maryland, is a research
and development company dedicated to commercializing medical treatment systems
for cancer and other diseases using focused heat technology delivered by
patented microwave technology. Celsion has research, license or
commercialization agreements with leading institutions such as Duke University
Medical Center, Massachusetts Institute of Technology, Harbor UCLA Medical
Center, the University of California at San Francisco, the Center for Breast
Surgery at Columbia Hospital in Florida, Montefiore Medical Center, Memorial
Sloan Kettering Cancer Center in New York and Duke University. For more
information on Celsion, visit our website: http//www.celsion.com.

Forward-looking statements in this release are made pursuant to the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995.
Investors are cautioned that such forward-looking statements involve risks and
uncertainties including, without limitation, unforeseen changes in the course of
research and development activities and in clinical trials; possible changes in
cost and timing of development and testing, capital structure, and other
financial items; changes in approaches to medical treatment; introduction of new
products by others; possible acquisitions of other technologies, assets or
businesses; possible actions by customers, suppliers, competitors, regulatory
authorities; and other risks detailed from time to time in the Company's
periodic reports filed with the Securities and Exchange Commission.
                                      ####